Astrazeneca | chemanager-online.com - Chemistry and Life Science

Jun. 11, 2019
News & Opinions
North America Leads Pharma Sales Outlook
North America should continue to lead global pharmaceutical sales up to 2022, with $635 billion in revenue expected that year, drugmaker AstraZeneca said in a recently published outlook on the industry.
May. 08, 2019
News & Opinions
AstraZeneca and Transgene Link on Immunotherapy
Anglo-Swedish drugmaker AstraZeneca is to collaborate with French biotech Transgene, part of Institut Mérieux, to discover and develop immunotherapies for treating cancers and infectious diseases.
Apr. 03, 2019
News & Opinions
AstraZeneca in $6.9 Billion Rights Share Deal
In a move to accelerate the development of its oncology franchise, AstraZeneca has agreed a $6.9 billion deal with Japanese pharma major Daiichi Sankyo to share rights to a new breast cancer drug called DS-8201. ...
Dec. 14, 2018
News & Opinions
AVEO and AstraZeneca Link on Lung Cancer
US biopharma AVEO Oncology is collaborating with Anglo-Swedish drug major AstraZeneca on a combined treatment for liver cancer. ...
Nov. 14, 2018
News & Opinions
AstraZeneca Sells Synagis Rights to Sobi
Anglo-Swedish drugmaker AstraZeneca has sold US right for its Synagis infant respiratory drug to Swedish Orphan Biovitrum (Sobi) for an upfront sum of $1.5 billion. The payment consists of $1 billion in cash and $500 million in Sobi ...
Nov. 09, 2018
News & Opinions
AstraZeneca Sells Rights to Respiratory Drugs
AstraZeneca, the British-Swedish pharma major, is selling rights outside the US for the respiratory drugs Alvesco, Omnaris, and Zetonna. Buyer is Zug, Switzerland-based Covis Pharma, which acquired the US ...
Nov. 08, 2018
News & Opinions
AstraZeneca Sells Drug Rights to Grünenthal
AstraZeneca is selling certain rights to Nexium and Vimovo to German drugmaker Grünenthal, having decided the drugs falls outside its main therapy areas of oncology, cardiovascular, renal & metabolism and respiratory.
Jul. 31, 2018
News & Opinions
AstraZeneca sells Atacand Rights
Anglo-Swedish drugmaker AstraZeneca has agreed to sell commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe to Germany’s Cheplapharm ...
Mar. 05, 2018
News & Opinions
AstraZeneca Creates Viela Bio from MedImmune Arm
MedImmune, the biologics R&D arm of Anglo-Swedish drugmaker AstraZeneca, is spinning out six molecules from its early-stage inflammation and autoimmunity programs into new independent biotech, Viela Bio.
Mar. 01, 2018
News & Opinions
AstraZeneca’s Imfinzi Gets US Nod for Lung Cancer
The US Food and Drug Administration (FDA) has approved AstraZeneca and MedImmune’s immunotherapy Imfinzi (durvalumab) to treat patients with a certain form of lung cancer. ...

12 3 4 5 6 7 8…

Register now!

The latest information directly via newsletter.

GIT Verlag